Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6843 USD | -2.24% | +3.52% | -7.90% |
Sales 2024 * | 5.59M 447M | Sales 2025 * | 3.67M 294M | Capitalization | 37.41M 2.99B |
---|---|---|---|---|---|
Net income 2024 * | -63M -5.04B | Net income 2025 * | -66M -5.28B | EV / Sales 2024 * | 4.83 x |
Net cash position 2024 * | 10.4M 833M | Net Debt 2025 * | 29.1M 2.33B | EV / Sales 2025 * | 18.1 x |
P/E ratio 2024 * |
-0.63
x | P/E ratio 2025 * |
-0.67
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.57% |
Latest transcript on Cara Therapeutics, Inc.
1 day | -2.24% | ||
1 week | +3.52% | ||
Current month | -24.80% | ||
1 month | -6.29% | ||
3 months | +18.70% | ||
6 months | -40.50% | ||
Current year | -7.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 05/08/18 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 11/09/22 |
Scott Terrillion
CMP | Compliance Officer | 61 | 31/10/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 30/06/10 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 15/07/14 |
Helen Boudreau
BRD | Director/Board Member | 58 | 01/08/23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.20% | 35 M€ | +18.97% | - | |
1.29% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.6843 | -2.24% | 169,234 |
25/04/24 | 0.7 | +4.23% | 319,087 |
24/04/24 | 0.6716 | -5.02% | 217,430 |
23/04/24 | 0.7071 | -3.19% | 181,920 |
22/04/24 | 0.7304 | +10.50% | 346,171 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.90% | 37.41M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- CARA Stock